Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Licenses Prenatal Dx Patents from Isis Innovation

NEW YORK, Oct. 20 (GenomeWeb News) - Sequenom today said it has acquired from Isis Innovation exclusive rights in certain countries to non-invasive prenatal diagnostic intellectual property.


The IP, which is covered in the United States, United Kingdom, and other countries in Europe, covers non-invasive prenatal genetic testing on fetal nucleic acids derived from plasma or serum. It includes tests for such disorders as cystic fibrosis, hemoglobinopathies, and chromosomal aneuploidies, and enables them to be performed on any platform including mass spectrometry and real time PCR.


Financial terms include up-front fees, milestone payments, and royalties on product sales. Isis is the tech-transfer company of the University of Oxford.

"The licensed rights enable the development and performance of tests on any relevant platform, including [Sequenom's flagship] MassArray system," Harry Stylli, Sequenom's president and CEO, said in a statement.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.